Skip to main content

Form 8.5 (EPT/RI) – Advanced Medical Solutions Group plc – Amendment

AMENDMENT – FORM 8.5 (EPT/RI)  PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Name of exempt principal trader: Investec Bank plc(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree Advanced Medical Solutions Group Plc(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Advisor & Joint Broker to Advanced Medical Solutions Group plc(d)        Date dealing undertaken: 11th May 2026(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party...

Continue reading

KOIL Energy Solutions Announces Dates for First Quarter Earnings Release and Conference Call

HOUSTON, May 12, 2026 (GLOBE NEWSWIRE) — Koil Energy Solutions, Inc. (OTCQB: KLNG), a specialist in deepwater energy production and distribution equipment and services, announced today that it will report its first quarter 2026 results on Friday, May 15, 2026, before the market opens. KOIL will host an investor conference call to review its first quarter 2026 results on Friday, May 15, 2026, at 10:00am Eastern Time. Interested parties may listen to the call through a webcast link or using the dial in numbers. (See below details.) PARTICIPANT WEBCAST LINK: https://edge.media-server.com/mmc/p/hcndufov PARTICIPANT DIALS:PARTICIPANT DIAL IN (TOLL FREE) 1-833-630-1956PARTICIPANT INTERNATIONAL DIAL IN 1-412-317-1837 The earnings release and a replay of the conference call will also be available on the Company’s website, www.koilenergy.com,...

Continue reading

Nuclear Diamond Batteries, Inc. (OTC: NDBI) Receives Second U.S. Patent Allowance Advancing Commercialization of Ultra-Long-Life Nuclear Diamond Battery Platform

Mesquite, NV, May 12, 2026 (GLOBE NEWSWIRE) — MESQUITE, Nev., May 12, 2026 (GLOBE NEWSWIRE) — Nuclear Diamond Batteries, Inc. (OTCID: NDBI) (“NDBI” or the “Company”), a developer of next-generation nuclear diamond battery technologies through its majority-owned subsidiary AtomiQ, Inc., today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for 19 claims under U.S. patent application No. 17/928,967 covering a specialized high-porosity electrode architecture designed for advanced nuclear diamond battery systems. The newly allowed patent relates to a metal-organic framework (“MOF”) electrode coated with carbon nano-onion structures to be engineered in order to significantly improve charge storage, energy transfer efficiency, and long-term stability within nuclear diamond...

Continue reading

Regarding the supplement of the agenda of the Annual General Meeting of Shareholders of AB “Novaturas”

By the initiative and decision of the Board of AB “Novaturas”, company code 135567698, with its registered office at A. Mickevičiaus st. 27, Kaunas, the Republic of Lithuania (hereinafter – the Company), the agenda of the Annual General Meeting of Shareholders of the Company to be held on 27 May 2026 (hereinafter – the Meeting), as indicated in the notice of convening the Meeting of 4 May 2026, has been supplemented with agenda items No 6 -10. Agenda of the Meeting (including its supplemented items):The Company’s consolidated management report for 2025. The independent auditor’s report on the Company’s audited annual financial statements and the Company’s consolidated financial statements for 2025. Approval of the Company’s audited annual financial statements and the Company’s consolidated financial statements for 2025. Consent to the...

Continue reading

BOSS Money Digital Customers Send Record Remittances to Mom for Mother’s Day

Send Volume to Countries Celebrating Mother’s Day Jumps 49% Year-over-Year NEWARK, N.J., May 12, 2026 (GLOBE NEWSWIRE) — BOSS Money, the international money remittance service of IDT Corporation (NYSE: IDT), today announced that its customers sent moms a record amount of principal and remittances using the BOSS Money and BOSS Revolution apps during the week leading up to and including Mother’s Day on May 10th, 2026. For the week ended May 10th, 2026, BOSS Money digital customers sent 49% more principal via 27% more remittances than last year to the eight BOSS Money destination countries that celebrated Mother’s Day this past weekend, including Mexico, Guatemala, Honduras and El Salvador. BOSS Money is a leading digital-first money remittance provider. 87% of all BOSS Money transfers during the week leading up to Mother’s Day were...

Continue reading

22nd Century Group, Inc. Highlights FDA Filing of VLN® MRTP Renewal Applications for Scientific Review

FDA filing covers renewal applications for VLN® King and VLN® Menthol King, the first combusted cigarettes authorized as Modified Risk Tobacco Products, as 22nd Century advances its regulatory pathway for continued modified risk marketing status MOCKSVILLE, N.C., May 12, 2026 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a tobacco harm reduction company focused on reduced nicotine innovation, today highlighted that the U.S. Food and Drug Administration has filed for scientific review two Modified Risk Tobacco Product, or MRTP, renewal applications for the Company’s VLN® King and VLN® Menthol King combusted, filtered cigarettes. The FDA filing marks an important step in the regulatory process for the continued marketing of these products with authorized modified risk claims. VLN® King and VLN® Menthol King were originally...

Continue reading

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

CBeyond™ Expansion Study (Part C) initiated; Cohort Review Committee review scheduled for May 18, 2026, to evaluate available safety data and potential progression to Cohort 2SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the first quarter ended March 31, 2026, along with recent business updates and anticipated milestones. “Since our March update, execution has focused on turning CBeyond into a Phase 2b-ready development program,” said Punit Dhillon, President & CEO of Skye. “We have now initiated enrollment of Cohort 1 of the CBeyond Expansion Study,...

Continue reading

Revision to Q1 2026 Trading Update

PRESS RELEASE Bloomberg (THEON:NA) / Reuters (THEON.AS)12 May 2026 –  Theon International Plc (THEON)  would like to notify market participants that the Q1 2026 Trading Update Report published on its website on 5 May 2026 has been revised on the Cash Flow Statement (page 15) to reflect a reclassification of the profit from financial assets measured at fair value to a non-cash item within the cash flow statement. This reclassification has no impact on the Company’s reported net debt position or any other details within the Q1 2026 Trading Update published via Euronext Amsterdam. The corrected Q1 2026 Trading Update is available on the Company’s website.For inquiries, please contact:Investor RelationsNikos MalesiotisE-Mail: ir@theon.comTel: +30 210 6772290 Media ContactElli MichouE-Mail: press@theon.comTel: +30 210...

Continue reading

RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2026 NET REVENUE +4.9%, EBITDA(1) +5.0%, ADJUSTED NET INCOME(2) +7.2%

Consolidated net revenue of € 713.4 million in the first quarter of 2026, +4.9% or +8.7% on a like-for-like basis(3) at constant exchange rates (CER); adverse FX impact of € 29.1 million (-4.3%) EBITDA(1) of € 283.6 million, +5.0%, margin on net revenue of 39.7%         Adjusted net income(2) of € 188.1 million, +7.2%, margin on net revenue of 26.4%         Net income of € 153.1 million, +22.4% Free cash flow(4) of € 92.1 million, -€ 66.7 million vs prior year Net debt(5) at € 1,985.2 million, just below 2.0x EBITDA FY 2026 financial targets confirmed Primary endpoint met in pasireotide (Signifor®) Phase 2 trial for the treatment of post-bariatric hypoglycemia (PBH); FDA meeting scheduled to discuss next steps Sutimlimab (Enjaymo®) to advance into a Phase 3 trial for the treatment of chronic immune thrombocytopenia (ITP) Performance...

Continue reading

South Jersey Industries, Inc. Commences Tender Offer to Purchase for Cash Any and All of the Outstanding 2018 Series A 3.70% Remarketable Junior Subordinated Notes due 2031

Folsom, NJ, May 12, 2026 (GLOBE NEWSWIRE) — Media Contact: SJI Media Relations609-561-9000 ext. 4131 media@sjindustries.com FOR IMMEDIATE RELEASE South Jersey Industries, Inc. Commences Tender Offer to Purchase for Cash Any and All of the Outstanding 2018 Series A 3.70% Remarketable Junior Subordinated Notes due 2031 FOLSOM, NJ, May 12, 2026 – South Jersey Industries, Inc. (“SJI”) today announced it has commenced a cash tender offer (the “Tender Offer”) to purchase for cash any and all of its outstanding 2018 Series A 3.70% Remarketable Junior Subordinated Notes due 2031 (the “Notes”) from each registered holder of the Notes (each, a “Holder,” and collectively, the “Holders”) subject to the terms specified in the Offer to Purchase, dated May 12, 2026 (as it may be amended or supplemented from time to time, the “Offer to Purchase”)...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.